Author's response to reviews

Title: A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors

Authors:

Jong Hyung Yoon (spree15@hanmail.net)
Mi Mi Kwon (rnjsalal@ncc.re.kr)
Hyeon Jin Park (hipark@ncc.re.kr)
Seog Yun Park (11740@ncc.re.kr)
Kun Young Lim (kylim@ncc.re.kr)
Jungnam Joo (jooj@ncc.re.kr)
Byung-Kiu Park (b kpark@ncc.re.kr)

Version: 4 Date: 9 August 2014

Author's response to reviews: see over
Aug 7, 2014

Dafne Solera
Editor-in-Chief, BMC Cancer

Dear Dr. Solera,

Please find the attached files for the manuscript (MS 2084626027120518) entitled “A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors” by Jong Hyung Yoon, Mi Mi Kwon, Hyeon Jin Park, Seog Yun Park, Kun Young Lim, Jungnam Joo, and Byung-Kiu Park* for consideration of publication in BMC Cancer. All authors have read and approved submission of this manuscript. This paper constitutes original material that has not been published previously in any language or format and has not been submitted elsewhere for print or electronic publication. This manuscript had been previously submitted to BMC Cancer for consideration as a full paper, and according to Decision on Aug 2nd 2014, the editor advised us a revised manuscript. Accordingly, we tried to respond to the comments point-by-point. We hope that the incorporated changes and additions allow the manuscript to be suitable for publication in the Journal. We thank you for your time and efforts on this matter.

Sincerely,

Byung-Kiu Park, M.D., Ph.D.

(Comment)

Please include funding sources in your acknowledgement section.

(Answer)

We did not have any funding sources for this study.

(Comment)
Please clarify whether you have consent to publish the clinical characteristics of the patients in table 1, otherwise please remove any patient identifiers such as age and gender.

(Answer)

We obtained consent to publish from UPNs 6 and 9 who are alive. You will find the consent form at the end of this covers letter. However, we could not obtain it from the remaining seven patients because they all died. According to the National Bioethics Committee (affiliated organization of the Ministry of Health and Welfare, Korea), additional consent may be waived for deceased or loss to follow-up patients once they agreed to participate in the study at the beginning.
CONSENT TO PERMISSION FOR PUBLICATION (논문출간동의서)

STUDY TITLE: Phase II trial of docetaxel and irinotecan (DI) for recurrent or refractory bone and soft tissue sarcomas (IRB No.: NCCCTS-08-322) (재발 또는 불용성 골연부 육종에서 docetaxel과 irinotecan 병합 항암화학요법의 치료 효과)

STATEMENT OF CONSENT (동의서)

I (UPN 6) and my parent, who agreed me to participate in this study, at this time allow the clinical data and radiological images of mine obtained during the study to be released in the academic paper. (본 연구에 참여하는데 동의하였던 나와 나의 부모는 이제 나의 임상자료와 영상자료가 학술지에 실리는 것을 허락합니다.)

NAME OF PARTICIPANT/PARENT (피험자/부모 성명): 이정호/나수진

SIGNATURE OF PARTICIPANT/PARENT (피험자/부모 서명): 01. 정호 / 나수진

PHONE: +82-(0)10-7210-1402

DATE (날짜): Aug 5, 2014

NAME & SIGNATURE OF PHYSICIAN (의사 성명 및 서명): BYUNG-KIU PARK, Bong-Kiu Park

DATE (날짜): Aug 5, 2014
CONSENT TO PERMISSION FOR PUBLICATION (논문출간동의서)

STUDY TITLE: Phase II trial of docetaxel and irinotecan (DI) for recurrent or refractory bone and soft tissue sarcomas (IRB No.: NCCCTS-08-322) (제발 또는 불용성 골연부 육중에서 docetaxel과 irinotecan 병합 항암화학요법의 치료 효과)

STATEMENT OF CONSENT (동의서)

I (UPN 9) and my parent, who agreed me to participate in this study, at this time allow the clinical data and radiological images of mine obtained during the study to be released in the academic paper. (본 연구에 참여하되 동의하였던 나의 부모는 이제 나의 임상자료와 영상자료가 학술지에 실리는 것을 허락합니다.)

NAME OF PARTICIPANT/PARENT (피험자/부모 성명): 김예원/김영자

SIGNATURE OF PARTICIPANT/PARENT (피험자/부모 서명): 김예원

PHONE: +82-(0)10-5746-8387

DATE (날짜): Aug 6, 2014

NAME & SIGNATURE OF PHYSICIAN (의사 성명 및 서명): BYUNG-KIU PARK, Byung-Kiu Park

DATE (날짜): Aug 6, 2014